Weekly Research Analysts’ Ratings Updates for uniQure (QURE)

Several analysts have recently updated their ratings and price targets for uniQure (NASDAQ: QURE):

• 8/1/2026 – uniQure was downgraded by Wall Street Zen from “hold” to “sell”.
• 7/30/2026 – uniQure had its price target lowered by Barclays PLC from $65.00 to $60.00. They now have an “overweight” rating on the stock.
• 7/30/2026 – uniQure had its price target raised by Wells Fargo & Company from $60.00 to $75.00. They now have an “overweight” rating on the stock.
• 7/29/2026 – uniQure was upgraded by Wolfe Research from “peer perform” to “outperform”. They now have a $65.00 price target on the stock.
• 6/29/2026 – uniQure had its price target raised by HC Wainwright from $50.00 to $80.00. They now have a “buy” rating on the stock.
• 6/26/2026 – uniQure had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 6/25/2026 – uniQure had its price target raised by Mizuho from $35.00 to $68.00. They now have an “outperform” rating on the stock.
• 6/18/2026 – uniQure had its price target raised by Royal Bank Of Canada from $35.00 to $65.00. They now have an “outperform” rating on the stock.
• 6/18/2026 – uniQure had its “buy” rating reaffirmed by HC Wainwright.
• 6/18/2026 – uniQure had its price target raised by Leerink Partners from $36.00 to $70.00. They now have an “outperform” rating on the stock.
• 6/18/2026 – uniQure had its price target raised by The Goldman Sachs Group, Inc. from $14.00 to $46.00. They now have a “neutral” rating on the stock.
• 6/18/2026 – uniQure was upgraded by Barclays PLC from “equal weight” to “overweight”. They now have a $65.00 price target on the stock, up from $25.00.
• 6/17/2026 – uniQure had its “positive” rating reaffirmed by Barclays PLC.
• 6/17/2026 – uniQure was upgraded by Cantor Fitzgerald from “neutral” to “overweight”. They now have a $61.00 price target on the stock.

Insider Activity at uniQure

In other news, insider Kylie O’keefe sold 15,936 shares of uniQure stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $27.06, for a total transaction of $431,228.16. Following the sale, the insider owned 108,864 shares of the company’s stock, valued at approximately $2,945,859.84. The trade was a 12.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Madhavan Balachandran sold 11,685 shares of the business’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $45.06, for a total transaction of $526,526.10. Following the transaction, the director owned 43,254 shares in the company, valued at $1,949,025.24. This represents a 21.27% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 388,229 shares of company stock valued at $16,817,099 over the last 90 days. Company insiders own 4.65% of the company’s stock.

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.